Atypical Infections in Chronic Myeloid Leukaemia- Staphylococcus furunculosis and Aspergillosis
Abstract
Incidence of opportunistic infection in patients of Chronic Myeloid Leukemia (CML) on Imatinib therapy is low. We report a case of a 47 year old lady, a known case of CML for one year on imatinib therapy who presented with CML in blast crisis with Staphylococcus furunculosis. Two weeks later she developed fever, cough and expectoration. She had cavitatory lesion in the right middle zone on chest x-ray. CECT Chest was suggestive of aspergilloma in right middle lobe. Infections in chronic myeloid leukemia are not very common. Also, developing such infections within such a short span of time, within one year of initiation of imatinib therapy is also rare. Hence, this case of CML with Staphylococcal furunculosis and Aspergillosis is being reported.
How to cite this article:
Mathews ST, Kumar N, Garg S, Mastebhakti B. Atypical Infections in Chronic Myeloid Leukaemia- Staphylococcus furunculosis and Aspergillosis. J Adv Res Med 2020; 7(1): 17-19.
DOI: https://doi.org/10.24321/2349.7181.202004
References
Massimo Breccia, Corrado Girmenia, Roberto Latagliata et al. Low Incidence Rate of Opportunistic
and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late
Chronic Phase. Mediterr J Hematol Infect Dis 2011; 3(1): e2011021.
Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F. Imatinib inhibits the
activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-1339.
Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL, Jr, Forman J. Imatinib mesylate inhibits antigen-specific
memory CD8 T cell responses in vivo. J Immunol 2007; 178: 2028-2037.
Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under
imatinib treatment. Blood 2008; 111: 5342-5349.
Schlaberg R, Fisher JG, Michael J Flamm, Vundavalli V Murty, Govind Bhagat, Bachir Alobeid. Chronic myeloid
leukemia and HIV-infection. Leuk Lymphoma 2008; 49(6): 1155-1160.
C Sillaber, Herrmann H, Bennett K, Rix U, Baumgartner U, Böhm A et al. Immunosuppression and atypical
infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009; 39(12): 1098-1109.
Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y et al. Epstein-Barr virus-associated
lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia. Haematologica
; 104(8): e376-e379.
Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J et al. Development of Varicella-Zoster
virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer
Res 2003; 9: 976-980.
Miyazawa Y, Ishikawa T, Sugisaki M, Matsumoto M, Akashi M, Ishizaki T et al. Mediastinal abscess due to
Aspergillus in a patient with atypical chronic myeloid leukemia, BCR-ABL1-negative. Rinsho Ketsueki 2020;
(2): 128-130.
Akiyama H, Maruyama T, Uetake T, Kawaguchi K, Sakamaki H, Onozawa Y. Systemic infection due
to atypical mycobacteria in patients with chronic myelogenous leukemia. Rev Infect Dis 1991; 13(5):
-818.
Guarderas J, Karnad A, Alvarez S, BerkSL. Corynebacterium minutissimum bacteremia in a patient
with chronic myeloid leukemia in blast crisis. Diagnostic Microbiology and Infectious Disease 1986: 327-330.
Pagano L, Caira M, Candoni A, Offidani M, Fianchi F, Martino B et al. The Epidemiology Of Fungal Infections
In Patients With Hematologic Malignancies: The SEIFEM-2004 Study. Haematologica 2006; 91: 1068-
Nasir T, Lee C, Lawrence AS, Brown JS. Invasive aspergillosis complicating treatment with tyrosine
kinase inhibitors. BMJ Case Rep 2019; 12(1): e226121. DOI: 10.1136/bcr-2018-22612
Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized
study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events
in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with
imatinib. Blood 2009; 114: 1126.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed
patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J
Clin Oncol 2008; 26: 4806-4813.
Speletas M, Timoleon-Achilleas V, Klara F, Dimitrios Plastiras, Kyriaki Kokoviadou, Antonios Antoniadis,
Ionnis Korantzis. Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid
leukemia receiving imatinib mesylate treatment. Medical Mycology 2008; 46(3): 259-263.
